Foresite Capital Management IV, LLC

CIK 0001704132 · WEST HOLLYWOOD, CA · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source ↗

Foresite Capital Management IV, LLC reported 6 positions worth $290.2M as of June 30, 2026 (13F filed August 14, 2026). Largest holding: PHVS (57.0%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.

$290.2M

2026 Q2

Positions

Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.

100.0%

Est. Net Flow (Q)

—

2026 Q2

Positions Changes Mix History BacktestPRO

6 positions shown

#	Symbol	Company	Type	Value ↓	% Port.	Shares	1Y	YTD
▸ 1	PHVS	Pharvaris N.V.	SH	$165.2M	56.95%	4,778,581	—	—
▸ 2	CYTK	CYTOKINETICS INC	SH	$60.9M	20.98%	714,695	—	—
▸ 3	EIKN	Eikon Therapeutics, Inc.	SH	$25.4M	8.74%	1,943,682	—	—
▸ 4	RLAY	Relay Therapeutics, Inc.	SH	$23.4M	8.06%	1,250,000	—	—
▸ 5	XENE	Xenon Pharmaceuticals Inc.	SH	$9.7M	3.33%	160,000	—	—
▸ 6	CRNXGBP	Crinetics Pharmaceuticals, Inc.	SH	$5.6M	1.93%	150,000	—	—

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Foresite Capital Management IV, LLC hold as of Q2 2026?

Foresite Capital Management IV, LLC reported 6 positions worth $290.2M in its Q2 2026 13F filing. Largest positions: PHVS (57.0%), CYTK (21.0%), EIKN (8.7%), RLAY (8.1%) and XENE (3.3%).

What did Foresite Capital Management IV, LLC buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Foresite Capital Management IV, LLC sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.